Research Insight
AstraZeneca and Incyte announce new lung cancer clinical trial collaboration
AstraZeneca and Incyte Corporation today announced a new collaboration to evaluate the efficacy and safety of Incyte’s Janus-associated kinase (JAK) 1 inhibitor, INCB39110, in...
Research Insight
AstraZeneca partners with peers and academia to establish translational research fund
AstraZeneca together with GlaxoSmithKline and Johnson & Johnson has partnered with three world-class universities, Imperial College London, the University of Cambridge and University College...
News
Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US
Cosentyx is the first and only interleukin-17A (IL-17A) inhibitor approved for adult patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) ...
News
Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that Lilly has submitted a new drug application (NDA) to the...
News
Lilly and Roche Diagnostics to Collaborate on Alzheimer’s Disease Adjunct Diagnostic Tool
Eli Lilly and Company (NYSE: LLY) today announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal...
Press Releases
U.S. Food And Drug Administration Approves Humulin® R U-500 KwikPen®
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY) Humulin® R U-500 KwikPen®(insulin human injection) 500 units/mL, a...
Press Releases
Lilly And Roche Diagnostics To Collaborate On Alzheimer’s Disease Adjunct Diagnostic ToolEli Lilly and Company (NYSE: LLY) today announced an arrangement to partner with...
Eli Lilly and Company (NYSE: LLY) today announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read